The Effect of High Dose Cholecalciferol on Arterial Stiffness and Peripheral and Central Blood Pressure in Healthy Humans: A Randomized Controlled Trial

Iain Bressendorff, Lisbet Brandi, Morten Schou, Birgitte Nygaard, Niels Erik Frandsen, Knud Rasmussen, Lars Ødum, Ove Vyff Østergaard, Ditte Hansen, Iain Bressendorff, Lisbet Brandi, Morten Schou, Birgitte Nygaard, Niels Erik Frandsen, Knud Rasmussen, Lars Ødum, Ove Vyff Østergaard, Ditte Hansen

Abstract

Background: Low levels of serum 25-hydroxy vitamin D are associated with increased arterial stiffness and hypertension. Supplementation with vitamin D precursors has been proposed as a treatment option for these conditions. We examined the effect of oral cholecalciferol on arterial stiffness and blood pressure in healthy normotensive adults.

Methods: 40 healthy adults were randomised in this double-blinded study to either oral cholecalciferol 3000 IU/day or matching placebo and were followed for 16 weeks to examine any effects on pulse wave velocity (PWV), augmentation index (AIx), peripheral and central blood pressure and 24-hour ambulatory blood pressure.

Results: 22 subjects in the cholecalciferol arm and 18 subjects in the placebo arm completed the 16 weeks of follow-up. There was no difference in changes in PWV, AIx corrected for heart rate or central or peripheral blood pressure between the two groups. There was no correlation between serum 25-hydroxy vitamin D and any of these parameters.

Conclusions: Oral cholecalciferol 3000 IU/day does not affect arterial stiffness or blood pressure after 16 weeks of treatment in healthy normotensive adults.

Trial registration: ClinicalTrials.gov NCT00952562.

Conflict of interest statement

Competing Interests: DH has received funding for other research projects from Abbott Laboratories A/S. D3 Pharmacy delivered the study medication. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Fig 1. Treatment Effect on 25-OH Vitamin…
Fig 1. Treatment Effect on 25-OH Vitamin D Levels.
Fig 2. Treatment Effect on 1,25-(OH) 2…
Fig 2. Treatment Effect on 1,25-(OH)2 Vitamin D Levels.
Fig 3. Treatment Effect on Pulse Wave…
Fig 3. Treatment Effect on Pulse Wave Velocity.
Fig 4. Treatment Effect on Augmentation Index.
Fig 4. Treatment Effect on Augmentation Index.
Fig 5. Treatment Effect on 24-hour Ambulatory…
Fig 5. Treatment Effect on 24-hour Ambulatory Blood Pressure.

References

    1. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–73.
    1. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11. 10.1161/CIRCULATIONAHA.107.706127
    1. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205(1):255–60. 10.1016/j.atherosclerosis.2008.10.033
    1. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. 10.1210/jc.2011-0385
    1. Institute of Medicine. Dietary Reference Ranges for Calcium and Vitamin D. 2010.
    1. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol. 2011;58(2):186–92. 10.1016/j.jacc.2011.02.051
    1. Mayer O Jr., Filipovsky J, Seidlerova J, Vanek J, Dolejsova M, Vrzalova J, et al. The association between low 25-hydroxyvitamin D and increased aortic stiffness. J Hum Hypertens. 2012;26(11):650–5. 10.1038/jhh.2011.94
    1. Seker T, Gur M, Kuloglu O, Kalkan GY, Sahin DY, Turkoglu C, et al. Serum 25-hydroxyvitamin D is associated with both arterial and ventricular stiffness in healthy subjects. J Cardiol. 2013;62(6):361–5. 10.1016/j.jjcc.2013.06.004
    1. Abdi-Ali A, Nicholl DD, Hemmelgarn BR, MacRae JM, Sola DY, Ahmed SB. 25-Hydroxyvitamin D status, arterial stiffness and the renin-angiotensin system in healthy humans. Clin Exp Hypertens. 2014;36(6):386–91. 10.3109/10641963.2013.827705
    1. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007;20(7):713–9.
    1. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307–14. 10.7326/0003-4819-152-5-201003020-00009
    1. Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol. 2013;28(3):205–21. 10.1007/s10654-013-9790-2
    1. Ke L, Mason RS, Kariuki M, Mpofu E, Brock KE. Vitamin D status and hypertension: a review. Integr Blood Press Control. 2015;8:13–35. 10.2147/IBPC.S49958
    1. Margolis KL, Martin LW, Ray RM, Kerby TJ, Allison MA, Curb JD, et al. A prospective study of serum 25-hydroxyvitamin D levels, blood pressure, and incident hypertension in postmenopausal women. Am J Epidemiol. 2012;175(1):22–32. 10.1093/aje/kwr274
    1. Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A. 1Alpha,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine. 2009;45(3):190–7. 10.1016/j.cyto.2008.12.009
    1. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–38.
    1. Nygaard B, Frandsen NE, Brandi L, Rasmussen K, Oestergaard OV, Oedum L, et al. Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial. PloS one. 2014;9(8):e102965 10.1371/journal.pone.0102965
    1. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S. Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2008;23(2):594–600.
    1. Weber T, Ammer M, Rammer M, Adji A, O'Rourke MF, Wassertheurer S, et al. Noninvasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens. 2009;27(8):1624–30. 10.1097/HJH.0b013e32832cb04e
    1. SphygmoCor Concise Software Guide (2008). In: , editor. 2011.
    1. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–605.
    1. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens. 2012;25(11):1215–22. 10.1038/ajh.2012.111
    1. Pilz S, Gaksch M, Kienreich K, Grubler M, Verheyen N, Fahrleitner-Pammer A, et al. Effects of vitamin d on blood pressure and cardiovascular risk factors: a randomized controlled trial. Hypertension. 2015;65(6):1195–201. 10.1161/HYPERTENSIONAHA.115.05319
    1. Yiu YF, Yiu KH, Siu CW, Chan YH, Li SW, Wong LY, et al. Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. Atherosclerosis. 2013;227(1):140–6. 10.1016/j.atherosclerosis.2012.12.013
    1. Ryu OH, Chung W, Lee S, Hong KS, Choi MG, Yoo HJ. The effect of high-dose vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 diabetes. Korean J Intern Med. 2014;29(5):620–9. 10.3904/kjim.2014.29.5.620
    1. Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, et al. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab. 2010;95(10):4584–91. 10.1210/jc.2010-0606
    1. Bischoff-Ferrari HA, Dawson-Hughes B, Stocklin E, Sidelnikov E, Willett WC, Edel JO, et al. Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Miner Res. 2012;27(1):160–9. 10.1002/jbmr.551
    1. Forman JP, Scott JB, Ng K, Drake BF, Suarez EG, Hayden DL, et al. Effect of vitamin D supplementation on blood pressure in blacks. Hypertension. 2013;61(4):779–85. 10.1161/HYPERTENSIONAHA.111.00659
    1. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, et al. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med. 2013;173(18):1672–9.
    1. Carrara D, Bernini M, Bacca A, Rugani I, Duranti E, Virdis A, et al. Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. J Renin Angiotensin Aldosterone Syst. 2014;15(1):82–7. 10.1177/1470320312471149
    1. Dalbeni A, Scaturro G, Degan M, Minuz P, Delva P. Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial. Nutr Metab Cardiovasc Dis. 2014;24(8):861–8. 10.1016/j.numecd.2014.02.015
    1. Scragg R, Slow S, Stewart AW, Jennings LC, Chambers ST, Priest PC, et al. Long-term high-dose vitamin D3 supplementation and blood pressure in healthy adults: a randomized controlled trial. Hypertension. 2014;64(4):725–30. 10.1161/HYPERTENSIONAHA.114.03466
    1. Al-Zahrani MK, Elnasieh AM, Alenezi FM, Almoushawah AA, Almansour M, Alshahrani F, et al. A 3-month oral vitamin D supplementation marginally improves diastolic blood pressure in Saudi patients with type 2 diabetes mellitus. Int J Clin Exp Med. 2014;7(12):5421–8.
    1. Arora P, Song Y, Dusek J, Plotnikoff G, Sabatine MS, Cheng S, et al. Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation. 2015;131(3):254–62. 10.1161/CIRCULATIONAHA.114.011732
    1. Mozaffari-Khosravi H, Loloei S, Mirjalili MR, Barzegar K. The effect of vitamin D supplementation on blood pressure in patients with elevated blood pressure and vitamin D deficiency: a randomized, double-blind, placebo-controlled trial. Blood Press Monit. 2015;20(2):83–91.
    1. Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, et al. Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. JAMA Intern Med. 2015;175(5):745–54. 10.1001/jamainternmed.2015.0237
    1. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007;282(41):29821–30.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera